Drugs / ASN008
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03798561 | Jan 2019 → Mar 2020 | atopic eczema | Asana BioSciences | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT05870865 | May → Nov 2023 | atopic eczema | Formation Bio, Inc. | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2020-03-10 | Asana BioSciences | Results Asana BioSciences Announces Topical Sodium Channel Blocker ASN008 Achieves Positive Results for the Treatment of Pruritus in Atopic Dermatitis; and Provides Update on JAK/SYK Inhibitor Gusacitinib in Phase 2 Studies for Chronic Hand Eczema and AD asanabio.com ↗
Asana BioSciences announced today positive topline results from a Phase 1b study evaluating the treatment of pruritus associated with atopic dermatitis (NCT03798561) for its topical sodium channel blocker, ASN008. |
| 2018-12-20 | Asana BioSciences | Regulatory Asana BioSciences Announces Initiation of First-in-Human Clinical Study with ASN008, a Novel Topical Product for the Treatment of Pruritus Associated with Atopic Dermatitis asanabio.com ↗
Asana BioSciences, a clinical stage biopharmaceutical company, announced today that it has been granted permission by the U.S. Food and Drug Administration (FDA) to start human clinical trials with ASN008, a topical gel for the treatment of pruritus (itch) associated with atopic dermatitis. |
All press releases naming this drug 2 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASN008 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05870865 ↗ |
| Action | Inhibit | “ASN008, a Permanently Charged Sodium Channel Blocker” PMID 32616515 ↗ Jul 2020 |
| Route | Topical | “Topical application of ASN008 gel” PMID 32616515 ↗ Jul 2020 |